Causes of death in men with localised prostate cancer: A nationwide, population-based study - Abstract

OBJECTIVE: To detail the distribution of causes of death for localised prostate cancer (PCa).

PATIENTS AND METHODS: PCBase Sweden links the Swedish National Prostate Cancer Register (NPCR) with other nation-wide population-based healthcare registers. We selected all 57,187 men diagnosed with localised PCa between 1997-2009 and their 114,374 age- and county-matched PCa-free control men. Mortality was calculated using competing risk regression analyses, taking into account PCa risk category, age, and Charlson comorbidity index (CCI).

RESULTS: In men with low risk PCa, all-cause mortality was lower compared to corresponding PCa-free men: 10-year all-cause mortality was 18% for men diagnosed at age 70 with CCI=0 and 21% among corresponding controls. 31% of these cases died of CVD compared to 37% of their controls. For men with low-risk PCa, 10-year PCa-mortality was 0.4%, 1%, and 3% when diagnosed at age 50, 60, and 70, respectively. PCa was the third most common cause of death (18%), after CVD (31%) and other cancers (30%). In contrast, PCa was the most common cause of death in men with intermediate and high-risk localised PCa.

CONCLUSIONS: Men with low-risk PCa had lower all-cause mortality than PCa-free men due to lower cardiovascular mortality, driven by early detection selection. However, for men with intermediate or high-risk disease, PCa death was substantial, irrespective of CCI, and this was even more pronounced for those diagnosed at age 50 or 60.

Written by:
Van Hemelrijck M, Folkvaljon Y, Adolfsson J, Akre O, Holmberg L, Garmo H, Stattin P.   Are you the author?
King's College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Unit, London, UK.

Reference: BJU Int. 2015 Jan 21. Epub ahead of print.
doi: 10.1111/bju.13059

PubMed Abstract
PMID: 25604807 Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.